ATXI:NSD-Avenue Therapeutics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 4.54

Change

-0.11 (-2.37)%

Market Cap

USD 0.08B

Volume

0.31M

Average Target Price

USD 6.00 (+32.16%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was incorporated in 2015 and is based in New York, New York.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-16 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

+10.94 (+6.84%)

USD64.03B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

-1.71 (-0.77%)

USD57.23B 21.49 15.27
REGN Regeneron Pharmaceuticals, Inc

+7.96 (+1.61%)

USD51.55B 15.77 12.24
ALXN Alexion Pharmaceuticals, Inc

+6.14 (+3.90%)

USD34.80B 57.92 33.71
BNTX BioNTech SE

+10.82 (+7.69%)

USD33.39B -99,999.99 N/A
BGNE BeiGene, Ltd

-2.27 (-0.74%)

USD27.77B N/A N/A
SGEN Seagen Inc

-4.14 (-2.77%)

USD27.13B 44.40 34.88
RPRX Royalty Pharma plc

+0.22 (+0.53%)

USD25.29B 22.60 15.33
GMAB Genmab A/S

+0.25 (+0.71%)

USD22.79B 26.59 3.26
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing ATXI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -23.70% 20% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -23.70% 20% F 10% F
Trailing 12 Months  
Capital Gain -51.75% 7% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -51.75% 7% F 3% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 20.32% 55% F 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.32% 55% F 70% C-
Risk Return Profile  
Volatility (Standard Deviation) 45.68% 69% D+ 37% F
Risk Adjusted Return 44.48% 71% C- 66% D
Market Capitalization 0.08B 14% F 17% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 38.48 3% F 3% F
Price / Cash Flow Ratio -16,882.43 100% A+ 100% A+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -112.48% 24% F 10% F
Return on Invested Capital -0.11% 85% B 50% F
Return on Assets -53.59% 13% F 4% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 1.85 65% D 56% F
Short Percent 6.76% 48% F 31% F
Beta 0.75 79% C+ 76% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.